### About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

### Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>fluticasone furoate-vilanterol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand Name</strong></td>
<td>Breo® Ellipta®</td>
</tr>
<tr>
<td><strong>Dosage Form</strong></td>
<td>100 mcg-25 mcg</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
<td>GlaxoSmithKline</td>
</tr>
</tbody>
</table>

#### Submission Review

<table>
<thead>
<tr>
<th>Use Reviewed</th>
<th>For the treatment of chronic obstructive pulmonary disease (COPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common Drug Review (CDR)</strong></td>
<td>Yes. The CDR recommended to list with criteria. Visit the CDR website for more details: <a href="http://www.cadth.ca/media/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf">www.cadth.ca/media/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf</a></td>
</tr>
<tr>
<td><strong>Drug Benefit Council (DBC)</strong></td>
<td>DBC met on October 20, 2014. DBC considered various inputs including: the final review completed by the Common Drug Review (CDR) on August 18, 2014, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from two patients; Clinical Practice Reviews from one General Physician and two specialists; as well as a Budget Impact Analysis.</td>
</tr>
</tbody>
</table>

#### Drug Coverage Decision

| **Limited Coverage benefit. Limited Coverage criteria is available at** [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority) |
| **Date**                   | May 15, 2015 |

**Reasons**

- Drug coverage decision is consistent with the DBC recommendation.
- The drug was similar to tiotropium (Spiriva®) and fluticasone propionate-salmeterol (Advair®) with respect to efficacy and safety.
- Based on economic considerations and the negotiated product price, the drug is cost effective and offers value for money.

**Other Information**

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.